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Abstract
Background
Pneumocystis jirovecii pneumonia (PCP) is a frequent opportunistic infection in immuno-
compromised patients. In literature, presentation and outcome of PCP differs between
patients with human immunodeficiency virus (HIV) infection and renal transplant recipients
(RTRs).
Methods
We conducted a cross-sectional study of patients with PCP based on the HIV and renal
transplant registries at our institution. Radiological and clinical data from all confirmed PCP
cases between 2005 and 2012 were compared.
Results
Forty patients were included: 16 with HIV and 24 RTRs. Radiologically, HIV patients had
significantly more areas of diffuse lung affection (81% HIV vs. 25% RTR; p = 0.02), more
ground glass nodules 5–10 mm (69% vs. 4%; p = <0.001) and enlarged hilar lymph nodes
were found only in HIV patients (44%). Cough and dyspnea were the most common clinical
signs (>80%) in both groups. Duration from illness onset to hospital presentation was lon-
ger in the HIV patients (median of 18 vs. 10 days (p = 0.02)), implying a less fulminant
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clinical course. Sixty percent of PCP cases in RTRs occurred >12 months after transplanta-
tion. Lengths of hospitalization, admission rates to the intensive care unit, and requirements
for mechanical ventilation were similar. Outcome in both groups was favourable.
Conclusions
While important differences in radiological presentation of PCP between HIV patients and
RTRs were found, clinical presentation was similar. PCP only rarely presented with fulmi-
nant respiratory symptoms requiring ICU admission, with similar results and outcomes for
HIV patients and RTRs. Early diagnosis and treatment is mandatory for clinical success.
Introduction
Pneumocystis jirovecii pneumonia (PCP) is one of the most frequent opportunistic infections
[1,2] and remains one of the leading causes of morbidity and mortality in HIV patients and
patients with impaired cell-mediated immunity [3].
In HIV patients, PCP typically manifests as an opportunistic infectionmainly in patients
with a CD4+ count of less than 200/μL. PCP is still one of the most frequent AIDS defining dis-
eases in resource rich settings and its occurrence is a marker of inadequate access to care or
poor adherence to drug therapy [4–6]. Overall, the incidence of PCP has decreasedwith wide-
spread use of chemoprophylaxis and the early introduction of antiretroviral therapy in HIV
patients. However, it remains a serious clinical problem due to the increasing use of cytotoxic
and immunosuppressant therapies in special populations. Risk factors for PCP in patients
without HIV infection are immunosuppressive treatment, e.g. glucocorticoids, and defects in
cell-mediated immunity [7,8]. Approximately 15% of patients who undergo solid organ trans-
plantation develop PCP in the absence of prophylaxis, especially in the early post-transplanta-
tion period [9,10]. In contrast to HIV patients, PCP in renal transplant recipients (RTRs) has
often been associated with fulminant respiratory failure and adverse outcomes [11].
PCP may be suspected based on the patient’s history, clinical signs and symptoms, labora-
tory findings and abnormal imaging studies, although initial chest X-rays may have no patho-
logical findings. A number of studies have been published on the different thoracic
manifestations of PCP in chest computed tomography (CT) scans in HIV patients [12–14]. In
general, the most pertinent finding is ground glass opacity (GGO) indicative of alveolar subto-
tal consolidation. Only few investigations have compared the clinical and radiological presenta-
tion of PCP in patient with distinct immunodeficiency in well-characterized groups, such as
RTRs and HIV patients [9,15]
HIV-related PCP can progress rapidly and can be severe and lethal, but findingsmade by
many working groups have shown that it progresses more slowly than PCP in other immuno-
compromised hosts. Early reports by Kovacs et al. [16] comparing the clinical manifestations
of HIV-associated PCP to features of PCP in subjects with other immunosuppressive disorders
identifiedmore indolent disease in HIV patients. Both groups, however, had poor survival
rates reaching almost 50% lethality. Later reports fromMansharamani and colleagues assessing
management and outcome patterns in a large group of HIV and non-HIV patients highlighted
the decliningmortality rate in HIV-related PCP of less than 7% in contrast to a rate of 40% in
non-HIV-infected PCP patients [11,16]. Recent studies have shown better survival of 86–92%
in HIV patients than in other groups of immunocompromised patients. This may be due to
increased PCP awareness and management in these patients during the past decades [17].
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In order to explore the current characteristics and outcomes of PCP infections, we con-
ducted a study based on two well-described immunosuppressed patient groups from our ter-
tiary care university hospital: adults with HIV, and RTRs. The primary aim of this study was to
compare CTmanifestation patterns, current clinical features, treatment modalities and out-
come in HIV patients and RTRs with confirmedPCP. Our hypothesis was that the different
underlying immunosuppressive mechanisms are reflected in both the clinical and radiological
manifestations and that outcomes of PCP differ in the two patient groups.
Materials and Methods
The BernUniversity Hospital (Inselspital) is a tertiary-care urban teaching hospital in Switzer-
land treating>40,000 inpatients and more than 500,000 outpatient consultations per year. The
current study was a cross-sectional analysis of confirmed cases of PCP, based on the local HIV
(www.shcs.ch) and transplant recipients cohorts.
All transplantations were performed according to the criteria of the Swiss national trans-
plant program based on the strict national laws and regulations for cell, tissue and organ dona-
tion (Swiss national law 810.21, https://www.admin.ch/opc/de/classified-compilation/
20051806/index.html) and conform to the international standards. None of the transplant
donors were coming from a vulnerable population and all (living) donors or next of kin pro-
vided written informed consent that was freely given. All research involving human partici-
pants have been approved by local the Cantonal Ethics of Berne (Kantonale Ethikkommission
Bern). All clinical investigations have been conducted according to the principles expressed in
the Declaration of Helsinki. Written Informed consent have been obtained from the registry
participants. The local HIV and renal transplant registries in our institution were screened
between 2005 and 2012 for patients with suspected PCP.
Inclusion was primary based on clinically and radiologically suspected PCP at admission
plus one of the following criteria for further confirmation: 1) microbiological confirmation of
Pneumocystis jirovecii by staining or PCR in sputum, bronchoalveolar lavage samples, or lung
biopsies 2) successful antimicrobial PCP treatment. Successful treatment was defined as rapid
clinical response, after initiation of the standard therapeutic regiment (trimethoprim-sulfa-
methoxazole) with accompanying resolution of typical radiological PCP findings during follow
up radiological examinations. Follow-up radiological examinations (i.e. CT-Scans and Chest
X-rays) were not systematically performed at predefined time points, since all the follow up
examinations and treatment decisions were at the discretion of treating physicians. The image
data was collected from the hospital PAC-system, anonymized and stored for further evalua-
tion. After the randomization process, two radiologists with 4 and 15 years of experience in
chest imaging performed a consensus read out of the cases. The readers were blinded to the
clinical data, symptoms and results. The readers were not involved in the initial interpretation
of the CT scans at the time of diagnosis.
Patient demographics and clinical outcomes
Outpatient and inpatient medical records and laboratory and microbiological findings of all
identified and confirmed cases in patients>18 years of age were retrospectively reviewed.Data
were recorded on standardized forms, including age, gender, underlyingmedical conditions,
HIV status and risk factors, peripheral CD4+ T-lymphocyte count, use of immunosuppressive
agents before PCP diagnosis, and use of chemoprophylaxis against PCP.
Pneumocystis Pneumonia in HIV Patients and Renal Transplant Recipients
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Image acquisition and interpretation
The radiologic images were acquired with 4-, 16-, 64- and 128-row scanners (all scanners were
manufactured by Siemens, Forchheim, Germany) with a slice thickness of 1 to 2 mm. The cases
were randomized before reading. The lung patterns were classified according to the Fleischner
Society recommendations on the stratification of lung disease. In addition, the radiologists
recorded the presence of pleural effusions and hilar and mediastinal lymphadenopathy
(node> 1 cm).
Statistical methods
For the statistical analysis, continuous data were compared using Student’s t test if normally
distributed, or else using the Mann-Whitney test. Statistical analyses of non-continuous
dichotomous data were compared using the chi-squared test or Fisher’s exact test, as appropri-
ate. The absolute frequency of each lung pattern was recorded and compared between groups.
In addition to the absolute pattern frequency, each patient was also analyzed individually. The
standard error of frequencywas assessed. All p-values were two-sided and the level of signifi-
cance was p =<0.05. A post-hoc Bonferroni test was applied to evaluate significant differences
between each assessed value. The statistical analysis was performedwith the MedCalc Version
7.6.0.0 statistical software (MedCalc Software, Ostend, Belgium).
Results
Clinical findings
Our analysis included 40 patients with confirmed PCP: 24 RTRs and 16 HIV patients. Clinical
and patient characteristics, treatment and PCP manifestation patterns, and outcomes in both
groups are presented in Table 1. Both groups consisted mainly of male patients and the RTRs
were significantly older than the HIV patients (p = 0.002). Unlike the HIV patients, due to the
chronic kidney disease in RTRs, patients had multiple comorbidities such as hypertension and
diabetes mellitus. Underlying pulmonarymedical conditions, including chronic lung disease,
were present to an equal extent in both groups. In 8/16 HIV patients PCP was the primary dis-
ease manifestation. In the remaining 8/16 HIV patients with previously established diagnosis 5
were ever under ART, but 4/5 patients were not under ART at PCP diagnosis (due to adherence
problems (n = 3) and stop after primary infection (n = 1)). The patient under ART at PCP diag-
nosis was already for the last 17 years under treatment with changing adherence, viral load
(23cp/ml) and CD4+ count (106 cells/μL) were low at PCP diagnosis. Concerning chemopro-
phylaxis, no RTRs were under prophylactic treatment at PCP diagnosis. PCP manifested in the
majority of RTRs cases (19/24, 79%) more than 6 months after transplantation (range 0–144
month). Regarding chemoprophylaxis in HIV, in the 8/16 patients with previous diagnosed
HIV, six had a CD4+ count below 200 cells/μL but only one was under prophylactic treatment
(and only for the last 4 weeks, the other patients were not adherent to follow up visits and/or
treatment), two patients had CD4+ counts of more than 200 cells/μL but with non-suppressed
viral loads. Immunosuppressive agents prior to PCP diagnosis and median dose per day in
RTRs at onset of PCP diagnosis are presented in Table 1. The standard immunosuppression
regiment in RTRs consisted of a triple therapy with long term steroids at a median dose of
12.5mg,Mycophenolate mofetil and calcineurin inhibitors in the majority of the patients. Over
half of the RTRs (14/24, 58%) had sought medical advice from our outpatient service in the last
weeks before PCP diagnosis due to a suspected viral upper respiratory tract infection. The most
common clinical PCP symptoms leading to hospital presentation, cough and dyspnea (>80%
in both groups), had been present for a longer period than in the HIV patients (median 18 vs.
Pneumocystis Pneumonia in HIV Patients and Renal Transplant Recipients
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Table 1. Demographics, clinical characteristics, and outcomes of PCP in renal transplant recipients vs. HIV-infected patients.
RTR(n = 24) HIV(n = 16)
Characteristic P-value
Demographics
Age, median (range) 60(31–77) 44(31–66) 0.002
Male, n (%) 15/24(63) 11/16(69) 0.75
Follow-up years (range) 5.1(0–8.3) 4.5(0.7–9.7) 0.82
Comorbidities
Chronic kidney disease, n (%) 24/24(100) 0/16(0) 0.0001
Hypertension, n (%) 21/24(88) 2/16(13) 0.0001
Heart insufficiency, n (%) 6/24(25) 1/16(6) 0.21
Diabetes mellitus, n (%) 9/24(38) 0/16(0) 0.03
Underlying pulmonary condition, n (%) 10/24(42) 6/16(38) 1.0
Clinical symptoms
Before PCP diagnosis, days (range) 10(1–49) 18(1–77) 0.02
Fever, n (%) 9/20(45) 3/7(43) 1.0
Cough, n (%) 19/22(86) 9/10(90) 1.0
Dyspnea, n (%) 18/22(82) 8/10(80) 1.0
Hospitalisation details
Admission to hospital, n (%) 24/24(100) 13/16(81) 0.06
Length of hospitalization, days (range) 11.5(3–75) 13(0–65) 0.8
ICU admission rate, n (%) 4/24(16) 1/16(6) 0.63
Need for mechanical ventilation, n (%) 3/24(13) 1/16(6) 0.63
Group-specific characteristics
Months elapsed, median (range)
from transplantation to PCP diagnosis 23(0–240)
from HIV diagnosis to PCP 108(0–240)
CD4+ count cl/μL median (IQR) 57(10–379)
PCP as first manifestation of HIV, n (%) 8/16(50)
ART naïve patients, n (%) 11/16(69)
Under ART at PCP diagnosis, n (%) 1/16(6)
Immunosuppressive agents used in RTRs
Calcineurin inhibitors, n (%) 14/24(58)
Cyclosporin, n (%) 10/24(42)
Median dose/day, mg (range) 200(125–375)
Tacrolimus, n (%) 4/24(17)
Median dose/day, mg (range) 4.5(3–11)
mTOR-Inhibitors, n (%) 6/24(25)
Sirolimus, n (%) 2/24(8)
Median dose/day, mg (range) 4.75(2.75–7)
Everolimus, n (%) 4/24(17)
Median dose/day, mg (range) 4.75(2.75–10)
Antimetabolic agents
Mycophenol mofetat, n (%) 18/24(75)
Median dose/day, mg (range) 2000(750–2000)
Prednison, n (%) 19/24(79)
Median dose/day, mg (range) 12.5(5–50)
Prophylaxis
Under PCP-Prophylaxis at Diagnosis, n (%) 0/24 (0) 1/16(6)
(Continued )
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10 days in RTR, p = 0.02). There were fewer hospitalizations for PCP treatment in HIV
patients. In contrast, all RTRs with PCP were hospitalized and most received adjunctive steroid
therapy (22/24, 92%). Fever was present in>40% of patients in both groups. In 38/40 patients
microbiological confirmation of Pneumocystis jirovecii was established by staining or PCR in
sputum, bronchoalveolar lavage samples, or lung biopsies. In two RTRs, without microbial
PCP confirmation, diagnosis was based upon typical clinical and biochemical constellation,
comparison of radiological patterns CT-scans at diseasemanifestation with previous radiologi-
cal findings, biochemical constellation and the clinical and radiological course of the disease
after of PCP therapy initiation. The length of hospitalization, admission to the intensive care
unit (ICU), and requirement for mechanical ventilation were similar between the groups
(Table 1). Only one patient from the RTR group died during hospitalization due to pulmonary
embolism. Three other patients died during follow up, two RTRs and one HIV Patient (all
because of acute pulmonary infection other than PCP). Concerning the PCP treatment regi-
men used, 38/40 patients were treated with trimethoprim-sulfamethoxazole. One HIV patient
with a mild allergic reaction to trimethoprim-sulfamethoxazole after therapy initiation and one
RTR with a known trimethoprim-sulfamethoxazole allergy received atovaquone suspension as
alternative treatment and secondary prophylaxis. Outcome of both patients was favorable. Kid-
ney function in RTRs worsened during infection, but reached baseline values after PCP treat-
ment completion. SecondaryPCP prophylaxis was recommended to all patients.
Radiological findings
The pattern frequency per lung segment is shown in Table 2 and the lung segment distribution
of PCP in the RTR group is shown in S1 Table. The most frequent pattern was patchy ground
glass opacity (GGO) in 92% of cases. The involvement of the lung was primarily multifocal
(88%) with slight peripheral predominance (58%) and subpleural sparing (33%). In the HIV
group, the most common pattern of PCP was patchy GGO (94%). The following patterns were
identified in the chest CTs: nodules<5 mm (88%), reticulation (81%), mosaic GGO (75%) and
nodules 5–10 mm (69%) (Table 2). Fifty percent of the patients had hilar or mediastinal lymph-
adenopathy. The peripheral regions of the lung were more affected (94%) than the perihilar
regions (81%), with dominant areas of diffuse patterning (81%; S1 Table).
HIV-associated PCP infection had a significantlymore diffuse pattern in 81% of patients
(seen in only 31% in the RTR group; p = 0.036). Ground glass nodules (GGNs) were also
Table 1. (Continued)
RTR(n = 24) HIV(n = 16)
Characteristic P-value
Treatment regimen
Trimethoprim-sulfamethoxazole1, n (%) 23/24(96) 15/16(94)
Duration, median days (IQR) 23(18–25) 21(11–34) 0.76
Receiving adjunctive steroid therapy, n (%) 22/24(92) 16/16(100) 0.51
Outcome
30-day all-cause mortality, n (%) 1/24(4) 0/16(0)
Died during follow-up, n (%) 2/24(8) 1/16(6) 1.0
Note: significant differences are given in bold font type; PCP = Pneumocystis jirovecii pneumonia, RTR = Renal transplant recipient, IQR = Interquartile
range.
1 The two patients not treated with trimethoprim-sulfamethoxazole received atovaquone suspension due to known or apparent trimethoprim-
sulfamethoxazole allergy.
doi:10.1371/journal.pone.0164320.t001
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significantlymore frequently of intermediate size (5–10 mm) in 69% of HIV patients compared
with only 4% in the RTR group (p< 0.0001). Hilar lymphadenopathy was identified in the
HIV group (44%) but not the RTR group (p = 0.01). Lung segments 1 and 5 were less affected
in the RTRs (S1 Table). The RTR and HIV groups showed patchy GGO in 92% and 94% of
patients, reticulation in 83% and 81%, GGN<5 mm in 67% and 88%, GGN 5–10 mm in 4%
and 68.8 ± 11.6%, mosaic GGO in 58% and 75%, and mediastinal lymphadenopathy in 50%
(Table 2). Distinct PCP manifestation patterns in HIV patients and RTRs are presented in Figs
1–4. Radiological follow-up was not performed systematically since the follow up examinations
and treatment decisions were at the discretion of treating physicians.
Discussion
The primary objectives of the present study were to compare radiologicalmanifestations, clini-
cal course, treatment and outcome of PCP betweenHIV patients and renal transplant recipi-
ents (RTRs). Similarities and important differences were found between the two groups, both
clinically and radiologically. With regard to distinct radiological patterns, enlarged hilar lymph
nodes were found only in HIV patients with PCP. Also, a significantlymore diffuse pattern of
scattering and larger GGNs were present in HIV patients.
Our radiological findings are in agreement with previous studies that have examined the
patterns in the lung associated with PCP in patients with and without HIV [3,18–20]. PCP
Table 2. Location and pattern frequency of PCP manifestations in renal transplant recipients and HIV-positive patients.
RTR (n = 24) HIV (n = 16) Fisher’s exact Test
Prevalence/Pattern %
frequency ± SD
Prevalence/Pattern %
frequency ± SD
Bonferroni corrected p-value
Location of disease
Central lung affected 54.2 ± 10.2 81.3 ± 9.8 1.00
Multifocal 87.5 ± 6.8 81.3 ± 9.8 1.00
Peripheral 58.3 ± 10.1 93.8 ± 6.1 0.55
Diffuse 25.0 ± 8.8 81.3 ± 9.8 0.02
Subpleural sparing 33.3 ± 9.6 50.0 ± 12.5 1.00
% Symmetric involvement of both lungs 60.8 ± 23.8 65.9 ± 28.1 1.00
Patterns
Consolidation All consolidations 20.8 ± 8.3 31.3 ± 12.5 1.00
Bronchopneumogram present 12.5 ± 6.8 18.8 ± 9.8 1.00
Interstitial patterns Reticulation 83.3 ± 7.6 81.3 ± 9.8 1.00
Arcades 12.5 ± 6.8 50.0 ± 12.5 0.21
Linear stripe 41.7 ± 10.1 50.0 ± 12.5 1.00
Cysts 10.3 ± 5.7 31.3 ± 11.6 1.00
Ground glass patterns Diffuse 16.7 ± 7.6 56.3 ± 12.4 0.31
Patchy 91.7 ± 5.6 93.8 ± 6.1 1.00
Mosaic 58.3 ± 10.1 75.0 ± 10.8 1.00
Nodule <5 mm 66.7 ± 9.6 87.5 ± 8.3 1.00
Nodule 5–10 mm 4.2 ± 4.1 68.8 ± 11.6 0.0004
Others Pleural effusion 8.3 ± 5.6 12.5 ± 8.3 1.00
Pneumothorax 4.2 ± 4.1 6.3 ± 6.1 1.00
Hilar lymphadenopathy 0.0 ± 0.0 43.8 ± 12.4 0.01
Mediastinal lymphadenopathy 16.7 ± 7.6 50.0 ± 12.5 1.00
Note: significant differences are given in bold font type; RTR = Renal transplant recipient, IQR = Interquartile range, SD = standard deviation.
doi:10.1371/journal.pone.0164320.t002
Pneumocystis Pneumonia in HIV Patients and Renal Transplant Recipients
PLOS ONE | DOI:10.1371/journal.pone.0164320 November 8, 2016 7 / 13
shows a predilection for the upper lobes; also, subpleural sparing and asymmetric distribution
of GGOwere present in both of our groups. By further separating GGO into diffuse and patchy
Fig 1. A) 45-year-old HIV-positive male patient with PCP with typical diffuse ground glass opacities in both lungs. B) 58-year-
old male patient 5 years after kidney transplantation who developed PCP with multifocal patchy ground glass opacities and
reticulation.
doi:10.1371/journal.pone.0164320.g001
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Fig 2. HIV-positive individual (49-year-old, male), CDC stage C3 with PCP. Faint, peripheral ground glass opacities with diffuse distribution in the upper
and lower lobes in both lungs. This finding was significantly more frequent in HIV-positive individuals. Subpleural sparing is also present.
doi:10.1371/journal.pone.0164320.g002
Fig 3. 55-year-old HIV positive male patient with PCP presenting with ground glass nodules in a diffuse distribution, predominantly in the right
lower lobe (circles in image A and B). This finding was significantly more prevalent in the HIV-positive study population. Patchy opacifications are also
evident in the left lower lobe.
doi:10.1371/journal.pone.0164320.g003
Pneumocystis Pneumonia in HIV Patients and Renal Transplant Recipients
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consolidations, we were able to demonstrate that a diffuseGGO pattern was predominantly
present in the HIV patients. PCP affected a greater lung volume in HIV patients than RTRs
and displayed a wider variety of patterns, although cystic lesions have been identifiedmore
often in HIV patients. Interestingly, this radiological pattern is now being seen less frequently
[3].
A further radiological pattern seenmuch more often in our HIV patients was the high fre-
quency of GGNs with a diameter of 5–10 mm. These sub-solid nodules were very rare in our
RTRs, which may reflect partial granulomatous inflammation with subtotal alveolar consolida-
tion as a response to PCP [14]. Enlarged hilar lymph nodes occurred only in our HIV patients,
which may suggest that the lymph nodemay be associated with the HIV as the primary infec-
tion and not with the PCP [13]. The absence of pneumothorax may reflect the timely detection
and appropriate treatment of the disease, thus reducing PCP-associated complications.
Regarding the clinical course, the period between onset of symptoms and diagnosis in RTR
was significantly shorter than in HIV patients. Although we confirm that the course of PCP in
HIV patients is often that of a gradually progressive disease with distinct clinical and radio-
graphic manifestation patterns different from those in RTR, our findings are not in agreement
with those of numerous published studies that report different outcomes for PCP in HIV
patients and otherwise immunosuppressed patients, with unfavorable outcomes in the latter
[14,16,21]. The clinical course in our groups of patients was similar, with prolonged symptoms
present before diagnosis, although of longer duration and less marked in our HIV patients.
Most RTRs had respiratory symptoms before PCP was diagnosed. This initial clinical charac-
teristic may reflect a less acute course for PCP in RTRs or a triggering upper respiratory co-
infection, as reported by earlier studies [9,21,22].
Fig 4. 70-year old, male RTR presenting with PCP. Bilateral, patchy consolidations with areas of ground glass attenuation. Septal thickening in the outer
portions of both lungs is present. Also, bilateral, peribronchial cuffing can be seen. Note the absence of hilar lymphadenopathy.
doi:10.1371/journal.pone.0164320.g004
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Nearly two-thirds of the RTRs developed PCP more than one year after transplantation, at a
time when routine PCP prophylaxis is no longer being given. The durations of hospitalization,
rates of acute respiratory failure, and need for mechanical ventilation were similar in our HIV
patients and RTRs, and we also observed favourable outcomes in RTRs.
Also, almost all of our RTRs received adjunctive steroid therapy after PCP diagnosis. How-
ever, it remains unclear whether the intermittent higher steroid dose (prophylactic stress dose)
given to the RTRs because of the suspected prodromal respiratory co-infection before PCP
becamemanifest might increase the risk of developing PCP or contribute to the favorable out-
come.We plan subsequent studies to explore the transmission dynamics and the influence of
intensified immunosuppression (e.g. due to antirejection therapies) in early- vs. late-onset PCP
in our RTRs.
Our findings have important clinical implications for caregivers of renal transplant and
HIV-infected patients. First, in contrast to prior reports, the clinical course of PCP seems to
be more subtle and is now rarely life-threatening in both in HIV and non-HIV patients,
since only few of our patients had to be admitted to ICU and neededmechanical ventilation.
Despite the overall favorable outcome in our patients, RTRs should be observed carefully,
and since PCP may present with a late onset and initial chest X-ray findings may be unspe-
cific, further radiological procedures including CT imaging appear to be mandatory in
transplant and immunocompromised patients [12,23]. Second, our findings might reflect
the changes in clinical PCP awareness, time of diagnosis and more rapid treatment in high-
risk populations, resulting in decreasedmorbidity and mortality due to PCP. The impor-
tance of appropriate and timely PCP prophylaxis must also be emphasized, since improve-
ments in implementing preventive measures can further decrease hospital admissions and
adverse outcomes [24].
Our study has several limitations. Foremost, the relatively small numbers of patients and
single center design limits the generalizability of our results. Rates of PCP among solid organ
transplant recipients were reported to be lowest for RTR and highest among lung and heart-
lung transplant patients. Therefore, our results from RTR cannot be generalized to other
patient groups. Also in all but two patients microbiological confirmation of PCP was provided
by staining or PCR in sputum, bronchoalveolar lavage samples, or lung biopsies. In the remain-
ing two RTRs without definite microbial confirmation, PCP diagnosis was based upon typical
clinical and biochemical constellation, as well as radiological initial manifestation. These two
patients might have suffered from other parenchymal lung disease, but the clinical presentation
characteristic and radiological patterns were similar to other RTRs. Furthermore, we did not
fully address current patient lifestyles and the exact adherence to drug therapy, both factors
with a major impact on PCP manifestation and outcome. Additional studies that include large,
prospectively selected groups of PCP-infected immunocompromised patients should address
these shortcomings.
In conclusion, our radiological data suggest that PCP is associated with a distinct lung pat-
tern in HIV patients and RTRs. PCP only rarely presents nowadays with fulminant respiratory
symptoms requiring ICU admission, and this is also the case in heavily immunocompromised
patients such as RTRs. Early diagnosis and treatment is mandatory for clinical success.
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